Autoimmune pancreatitis - What we know and what do we have to know?

Published on Jul 17, 2021in Autoimmunity Reviews7.767
· DOI :10.1016/J.AUTREV.2021.102912
Ammar Qureshi , Youssef Ghobrial + 2 AuthorsKam A. Newman9
Estimated H-index: 9
(UCR: University of California, Riverside)
Source
Abstract
📖 Papers frequently viewed together
21 Citations
References100
Newest
PURPOSE OF REVIEW Type 2 autoimmune pancreatitis (AIP) is a rare inflammatory disease of the pancreas. Very few data have been published on this particular subtype, which differs from the 'classical' IgG4-related type 1 AIP in terms of pathological features, epidemiology and risk of relapse. The aim of the current review is to summarize the available literature, suggesting a diagnostic and therapeutic approach to this disease. RECENT FINDINGS Based on the International Consensus Diagnostic Crite...
2 CitationsSource
#1Martin Blaho (University of Ostrava)H-Index: 2
#2Petr Dítě (University of Ostrava)H-Index: 10
Last. Bohuslav Kianička (Masaryk University)H-Index: 5
view all 4 authors...
Autoimmune pancreatitis is a rare form of chronic pancreatitis. The first descriptions of the disease date back to the 1990s. Etiology is multifactorial, with the use of genetic, environmental and complex immunological mechanisms. It is classified into two subtypes. Type 1 is part of a group of diseases called IgG4-related disease. Clinically is autoimmune pancreatitis manifested by icterus and abdominal discomfort. It can rarely present as acute pancreatitis. There is also a completely asymptom...
3 CitationsSource
#1Yasuhiro Kuraishi (Shinshu University)H-Index: 4
#2Takeshi Uehara (Shinshu University)H-Index: 26
Last. Shigeyuki Kawa (Matsumoto Dental University)H-Index: 67
view all 7 authors...
Abstract Background/objectives Patients with autoimmune pancreatitis (AIP) sometimes progress to chronic pancreatitis (CP). We evaluated the ability of corticosteroids to prevent the progression to CP. Methods We defined patients with definitive findings of CP (stones in the main pancreatic duct [MPD] or multiple pancreatic calcifications) as having severe calcification (SC). A total of 145 AIP patients were enrolled. We measured the duration between AIP diagnosis and SC development and retrospe...
4 CitationsSource
#1Luca Barresi (ISMETT)H-Index: 22
#2Matteo Tacelli (ISMETT)H-Index: 5
Last. EndoscopistsH-Index: 1
view all 29 authors...
BackgroundAutoimmune pancreatitis (AIP) is a rare, and relatively new, form of chronic pancreatitis. The management of AIP can vary considerably among different centres in daily clinical practice.O...
8 CitationsSource
#1Ashish Khandelwal (Mayo Clinic)H-Index: 13
#2Dai InoueH-Index: 20
Last. Naoki Takahashi (Mayo Clinic)H-Index: 62
view all 3 authors...
Objective Since the time of inception of autoimmune pancreatitis (AIP), our knowledge of autoimmune pancreatitis has expanded significantly. The aim of this review is to provide an update on clinical manifestations, diagnosis, imaging features, and treatment of AIP.
10 CitationsSource
#1Atsushi Masamune (Tohoku University)H-Index: 67
#2Kazuhiro Kikuta (Tohoku University)H-Index: 32
Last. Kazuichi Okazaki (Kansai Medical University)H-Index: 85
view all 7 authors...
Background To further clarify the clinico-epidemiological features of autoimmune pancreatitis (AIP) in Japan, we conducted the fourth nationwide epidemiological survey.
33 CitationsSource
Autoimmune pancreatitis (AIP), a unique subtype of pancreatitis, is often accompanied by systemic inflammatory disorders. AIP is classified into two distinct subtypes on the basis of the histological subtype: immunoglobulin G4 (IgG4)-related lymphoplasmacytic sclerosing pancreatitis (type 1) and idiopathic duct-centric pancreatitis (type 2). Type 1 AIP is often accompanied by systemic lesions, biliary strictures, hepatic inflammatory pseudotumors, interstitial pneumonia and nephritis, dacryoaden...
9 CitationsSource
Autoimmune pancreatitis (AIP) is an entity that has been recognized since 1961. Prior to the discovery of elevated serum IgG4 as a useful biomarker for its diagnosis, Dr. Yoshida in 1995 first described the entity of AIP, which in retrospect closely resembles the current concept of type 1 AIP. Since the discovery of IgG4 as a biomarker (the IgG4-era), a novel concept of IgG4-related disease (IgG4-RD) has been accepted as being comprised of two subtypes of AIP: type 1 defined as the pancreatic ma...
8 CitationsSource
#1Rajib K Gupta (State University of New York Upstate Medical University)H-Index: 7
#2Azfar NeyazH-Index: 10
Last. Vikram DeshpandeH-Index: 120
view all 9 authors...
Background:Autoimmune pancreatitis (AIP) encompasses a heterogenous disease group that includes IgG4-related type 1 AIP and non–IgG4-related type 2 AIP. Clinically and on imaging, type 2 AIP mimics type 1 AIP, other forms of chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC); therefore
6 CitationsSource
#1Matteo Tacelli (University of Palermo)H-Index: 5
#2Ciro Celsa (University of Palermo)H-Index: 10
Last. Calogero Cammà (University of Palermo)H-Index: 76
view all 9 authors...
Background & Aims Risk for relapse after induction of remission with steroid therapy has been studied extensively in patients with autoimmune pancreatitis (AIP), but findings have been equivocal. We performed a systematic review and meta-analysis to estimate the relapse rate of AIP after initial remission after steroid treatment and to identify factors associated with relapse. Methods Three reviewers searched MEDLINE, SCOPUS, and EMBASE until July 2018 to identify studies on rate of relapse of A...
13 CitationsSource
Cited By0
Newest